Portopulmonary Hypertension: An Effect of Vasomodulation and Mortality Post-Transplant
DOI:
https://doi.org/10.12974/2312-5470.2014.01.02.1Keywords:
Portopulmonary hypertension, Liver transplant, vasodilator.Abstract
Introduction: Portopulmonary hypertension (PPH) complicates the perioperative conditions in patients who anticipate orthotopic liver transplant (OLT). PPH is rare-occurring in only 6% of those referred for OLT. There is decrease in survival with the moderate to severe PPH subgroup with OLT. Overall only a third live to 5 years time after transplant. Treatment of PPH with vasomodulative therapies before transplantation has increased survival both pre- and post-transplant. The purpose of this study is to report the mortality, prevalence of vasomodulator therapy in PPH before and after OLT depending on group severity.
Methods: This is a retrospective cohort study conducted from our liver transplant database over the course of 15 years. Patients were selected if they were diagnosed with PPH and received OLT. There pulmonary pressures were recorded preoperatively thereby categorizing patients into severity stages. Patient age, ethnicity, gender, BMI, and concurrent comorbidities were also included. The outcomes were overall and group-specific survival, and vasomodulator therapy types used.
Results: The most common cause of liver failure in both groups was Hepatitis C and alcohol-induced cirrhosis. Overall mortality was 50%. There was an increase in use of sildenafil and epoprostenol post-transplant in the PPH group. Forty-percent of transplanted patients lived to more than 1200 day end-point. Patients in moderate to severe had a sustained survival rate from years 1-5 post-transplant.
Conclusions: Patients with pulmonary vascular disease have a complicated liver transplant course specifically with moderate to severe PPH. This retrospective study suggests that in the setting of PPH and liver transplant, mortality is greatly improved after OLT with long-term treatment with vasomodulators, specifically those with moderate-severe disease.
References
Kawut SM, Krowka MJ, Trotter JF, et al. Clinical risk factors for portopulmonary hypertension. Hepatology 2008; 48(1): 196-203. http://dx.doi.org/10.1002/hep.22275
Colle I, Van Steenkiste C, Geerts A, et.al. Hepatopulmonary syndrome and portopulmonary hypertension: what's new? Acta Gastroenterol Belg 2007; 70(2): 203-209.
Colle IO, Moreau R, Godinho E, et al. Diagnosis of Portpulmonary Hypertension in Candidates for Liver Transplant: A Prospective Study. Hepatology 2003; 37: 401- 409. http://dx.doi.org/10.1053/jhep.2003.50060
Krowka MJ, Mendel MS, Ramsay MA, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transplant 2004; 10(2): 174-182. http://dx.doi.org/10.1002/lt.20016
Ramsay MA. Portopulmonary hypertension and hepatopulmonary syndrome, and liver transplantation. Internat Anes Clin 2006; 44(3): 69-82. http://dx.doi.org/10.1097/01.aia.0000210800.60630.ac
Houlihan DD, Holt A, Elliot C, Ferguson JW. Review article: liver transplant for the pulmonary disorders of portal hypertension. Aliment Pharmacol Ther 2013; 37: 183-194. http://dx.doi.org/10.1111/apt.12140
Schott R, Chaouat A, Launoy A. Improvement of Pulmonary Hypertension After Liver Transplantation. CHEST 1999; 116(6): 1748-1749. http://dx.doi.org/10.1378/chest.115.6.1748
Clift PF, Townsend JN, Bramhall S, et al. Successful treatment of severe portopulmonary hypertension after liver transplantation by bosentan. Transplantation 2004; 77(11): 1774-1776. http://dx.doi.org/10.1097/01.TP.0000131187.26530.41
Gough MS, White RJ, Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension. Liver Transplantation 2009; 15: 30-36. http://dx.doi.org/10.1002/lt.21533
Hemnes AR, Robbins IM, Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation. Liver Transplantation 2009; 15: 15-19. http://dx.doi.org/10.1002/lt.21479
Ashfaq M, Chinnakotla S, Rogers L, et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant 2007; 7: 1258-1264. http://dx.doi.org/10.1111/j.1600-6143.2006.01701.x
Kuo PC, Plotkin JS. Gaine S, et al. Portopulmonary Hypertension and the Liver Transplant Candidate. Transplantation 1999: 67(8): 1087-1093. http://dx.doi.org/10.1097/00007890-199904270-00001
Swanson KL, Wiesner RH, Nyberg SL, et al. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant 2008; 8: 2445-53. http://dx.doi.org/10.1111/j.1600-6143.2008.02384.x